New York (PRWEB) July 22, 2009
SpringTree Special Opportunities Fund, LP ("SpringTree") announced today its AU$25,500,000 investment in Prima BioMed Ltd (ASX:PRR), an Australian Securities Exchange-listed oncology biotechnology company. KTA Capital acted as the exclusive financial advisor to SpringTree's general partner SpringTree Global Investors, LLC on the transaction. To view a copy of Prima BioMed Ltd's public announcement please click here http://www.asx.com.au/asxpdf/20090721/pdf/31jn69xw14p8wy.pdf .
About KTA Capital, LLC
KTA Capital is an investment bank headquartered in New York, USA. Its services include international investment banking across a wide range of industries, both in the equity capital and debt markets, as well as M&A advisory. In its business it leverages its relationships with literally hundreds of institutional investors, including hedge funds, mutual funds, private equity funds, venture capital funds, bond funds, mezzanine debt funds, private placement funds, investment advisers, national, regional and international banks, acquisitive industry participants and strategic cornerstone investors, family offices, merchant banks and sovereign wealth funds. KTA Capital is registered as a broker-dealer with the United States Securities and Exchange Commission and is a member of Financial Industry Regulatory Authority, Inc. (" FINRA").
Tel.: +1 646 707 4177
About SpringTree Global Investors, LLC
SpringTree Global Investors, LLC ( http://www.springtreegi.com ) is a New York-based asset management company that makes debt and equity investments in public companies around the world with a focus on small-cap and mid-cap companies requiring US$5-US$150 million in debt and/or equity. It invests across a broad range of industries and a wide range of geographies and economic environments.
Tel.: +1 212 255 3552